Corcept Therapeutics Incorporated· CORT
🇺🇸 US · LargeSP600NASDAQ
- Price
- $109.80
- Day
- -2.66%
- Mkt Cap
- $11.87B
- 52W Range
- $28.66 – $122.21
- Volume
- 1.09M
- Beta
- 0.46
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
FAS Wealth Partners Inc. increased its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 4.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 322,370 shares of the biotechnology company's stock after buying an additional 12,352 shares during
Read full article
Avidity Partners Management LP lifted its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 36.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,000 shares of the biotechnology company's stock after buying an additional 8,000 shares during the period.
Read full article
Corcept Therapeutics remains a 'Hold' as LIFYORLI's strong launch and clinical demand are already reflected in a premium valuation. LIFYORLI generated $47.6M in its first full quarter, with management targeting $1B+ US peak revenue and global NPV estimated at $4.24B. CORT's pipeline offers upside, notably with relacorilant in earlier PROC lines and EU approval pending, but non-LIFYORLI assets remain speculative.
Read full article
Corcept tops Q2 earnings estimates as Korlym growth and a strong Lifyorli launch lift revenues, prompting a higher 2026 top-line outlook.
Read full article
Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcript
Read full article
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2026. Financial Results “Our oncology and Cushing's syndrome businesses delivered strong results in the second quarter. In our oncology busi.
Read full article
Corcept Therapeutics NASDAQ: CORT reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing's syndrome franchise increased and its newly launched ovarian cancer therapy LIFYORLI contributed $47.6 million in its first quarter of availability.
Read full article
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.29 per share a year ago.
Read full article
Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Read full article
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Read full article
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).Conference Call InformationParticipants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN.
Read full article
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
Read full article